2186 Income Statement - TTM - Luye Pharma Group Ltd.

Income Statement (TTM)

Luye Pharma Group Ltd. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

	2020 09-30	2020 12-31	2021 03-31	2021 06-30	2021 09-30	2021 12-31	2022 03-31	2022 06-30	2022 09-30	2022 12-31	2023 03-31	2023 06-30	2023 09-30	2023 12-31	2024 03-31	2024 06-30	2024 09-30	2024 12-31	2025 03-31	2025 06-30
Revenue	5,864	5,540	5,534	5,529	5,365	5,200	5,150	5,099	5,541	5,982	6,008	6,035	6,089	6,143	6,228	6,314	6,187	6,061	6,115	6,168
Change (%)		-5.54	-0.10	-0.10	-2.97	-3.07	-0.97	-0.98	8.65	7.96	0.45	0.44	0.90	0.89	1.39	1.37	-2.00	-2.04	0.88	0.87
% of Revenue	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Cost Of Sales	1,547	1,549	1,666	1,783	1,793	1,803	1,705	1,606	1,724	1,841	1,921	2,001	1,970	1,939	1,957	1,974	1,996	2,017	2,031	2,045
Change (%)		0.16	7.54	7.01	0.58	0.58	-5.47	-5.78	7.31	6.81	4.35	4.16	-1.56	-1.58	0.91	0.90	1.09	1.08	0.68	0.68
% of Revenue	26.37	27.96	30.10	32.24	33.42	34.68	33.11	31.50	31.11	30.78	31.97	33.16	32.35	31.56	31.41	31.27	32.25	33.28	33.21	33.15

Gross Operating Profit	4,318	3,991	3,869	3,746	3,572	3,397	3,445	3,493	3,817	4,141	4,087	4,034	4,119	4,204	4,272	4,339	4,192	4,044	4,084	4,123
Change (%)		-7.58	-3.06	-3.16	-4.67	-4.90	1.42	1.40	9.27	8.48	-1.29	-1.31	2.11	2.07	1.61	1.58	-3.40	-3.52	0.98	0.97
% of Revenue	73.63	72.04	69.90	67.76	66.58	65.32	66.89	68.50	68.89	69.22	68.03	66.84	67.65	68.44	68.59	68.73	67.75	66.72	66.79	66.85

SG&A	2,302	2,185	2,151	2,116	2,196	2,276	2,301	2,327	2,365	2,403	2,557	2,711	2,705	2,700	2,564	2,428	2,413	2,398	2,496	2,593
Change (%)		-5.07	-1.59	-1.61	3.77	3.63	1.14	1.12	1.62	1.59	6.42	6.03	-0.20	-0.20	-5.05	-5.32	-0.60	-0.60	4.05	3.89
% of Revenue	39.25	39.45	38.86	38.27	40.93	43.76	44.69	45.64	42.68	40.17	42.55	44.92	44.43	43.95	41.16	38.45	39.00	39.57	40.81	42.03

R&D
Change (%)
% of Revenue

OpEx	4,608	4,551	4,659	4,767	4,802	4,837	4,824	4,811	5,002	5,193	5,339	5,486	5,371	5,256	5,142	5,029	4,977	4,925	5,051	5,178
Change (%)		-1.22	2.37	2.32	0.73	0.72	-0.27	-0.27	3.97	3.81	2.82	2.75	-2.10	-2.14	-2.16	-2.21	-1.03	-1.04	2.57	2.50
% of Revenue	78.57	82.16	84.19	86.22	89.51	93.01	93.67	94.34	90.28	86.81	88.86	90.90	88.20	85.55	82.56	79.65	80.43	81.25	82.61	83.95

Operating Income	1,257	988	875	762	563	363	326	288	539	789	669	549	718	887	1,086	1,285	1,211	1,137	1,063	990
Change (%)		-21.35	-11.47	-12.95	-26.15	-35.40	-10.31	-11.50	86.79	46.46	-15.21	-17.93	30.81	23.55	22.40	18.30	-5.78	-6.13	-6.45	-6.89
% of Revenue	21.43	17.84	15.81	13.78	10.49	6.99	6.33	5.66	9.72	13.19	11.14	9.10	11.80	14.45	17.44	20.35	19.57	18.75	17.39	16.05

Interest Expense	-411	-424	-411	-397	-398	-399	-409	-418	-445	-472	-518	-564	-620	-675	-661	-646	-604	-562	-592	-622
Change (%)		3.19	-3.18	-3.29	0.31	0.31	2.27	2.22	6.49	6.09	9.83	8.95	9.83	8.95	-2.15	-2.19	-6.55	-7.01	5.40	5.12
% of Revenue	-7.01	-7.65	-7.42	-7.18	-7.42	-7.68	-7.93	-8.19	-8.03	-7.89	-8.62	-9.35	-10.18	-11.00	-10.61	-10.24	-9.76	-9.27	-9.68	-10.09

Net Income	955	707	630	554	210	-134	-179	-224	190	605	531	458	495	533	652	770	621	472	434	397
Change (%)		-26.05	-10.81	-12.13	-62.13	-164.09	33.33	25.00	-185.01	217.63	-12.15	-13.84	8.17	7.55	22.33	18.25	-19.38	-24.03	-7.94	-8.63
% of Revenue	16.29	12.76	11.39	10.02	3.91	-2.58	-3.48	-4.39	3.44	10.11	8.84	7.59	8.13	8.67	10.46	12.20	10.04	7.79	7.10	6.44

Source: Capital IQ

Luye Pharma Group Ltd. - Income Statement (TTM)

Income Statement (TTM)

Other Listings

US:LYPHF
DE:LUP	€0.41